Particularly, Wang et al in a meta-analysis study showed that EZH2 overexpression correlates with poor prognosis in patients with non-small cell lung cancer [19] while Bachmann et al in a prospective analysis of 700 cancer patients demonstrated that EZH2 is a marker of increased aggressiveness in patients with melanoma and endometrial cancer consistently with the previous findings in patients with breast and prostate cancer [19, 20]. This evidence concerns the gene EZH2 and prostate cancer.